SLC6A1 and neurodevelopmental disorder: These critical domains are also identified using HPO analysis based on available clinical data, further emphasizing these as dominant symptoms of SLC6A1. Overall, this clinical assessment from the BGR gave a reasonable dataset for understanding the impact of the full spectrum and the severity of SLC6A1-neurodevelopmental disorders, and therefore an excellent comparison set for studying the variant of uncertain significance from the UF1.